How skin delivery of drugs can help treat breast cancer
Determinants of transdermal drug delivery to the normal and the radiated breast
This study is looking at whether delivering medication through the skin can be a helpful alternative for treating ductal carcinoma in situ (DCIS) of the breast, with the goal of reducing side effects compared to taking pills.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10559716 on NIH RePORTER |
What this research studies
This research investigates how transdermal drug delivery can be used as an alternative treatment for ductal carcinoma in situ (DCIS) of the breast. It focuses on the effectiveness of delivering medication through the skin, which may reduce the side effects associated with oral therapies. The study aims to understand the factors that affect how well drugs penetrate the skin and to compare the outcomes of transdermal versus oral treatments. By conducting clinical trials, the research seeks to establish whether skin-delivered therapies can provide similar benefits to traditional oral medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ductal carcinoma in situ (DCIS) who are seeking alternative treatment options.
Not a fit: Patients with advanced breast cancer or those who have not been diagnosed with DCIS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for women with DCIS, reducing reliance on oral therapies that have significant side effects.
How similar studies have performed: Previous research has shown promising results with transdermal drug delivery methods, indicating potential for success in this novel approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Khan, Seema Ahsan — Northwestern University at Chicago
- Study coordinator: Khan, Seema Ahsan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.